Johnson & Johnson (NYSE:JNJ) Q2 2024 Earnings Conference Call July 17, 2024 8:30 AM ET
Company Participants
Jessica Moore - Vice President, Investor Relations
Joe Wolk - Executive Vice President, Chief Financial Officer
Joaquin Duato - Chairman and Chief Executive Officer
Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals
Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech
John Reed - Executive Vice President, Innovative Medicine, R&D
Conference Call Participants
Chris Schott - JPMorgan
Larry Biegelsen - Wells Fargo
Louise Chen - Cantor Fitzgerald
Rick Wise - Stifel
Terence Flynn - Morgan Stanley
Josh Jennings - TD Cowen
Dave Risinger - Leerink Partners
Danielle Antalffy - UBS
Chris Shibutani - Goldman Sachs
Joanne Wuensch - Citibank
Operator
Good morning, and welcome to Johnson & Johnson's Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. [Operator Instructions]
I would now like to turn the conference to Johnson & Johnson. Please go ahead.
Jessica Moore
Hello, everyone. This is Jessica Moore, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of the second quarter business results and our full-year financial outlook for 2024. A few logistics before we get into the details. As a reminder you can find additional materials including today’s presentation and associated schedules on the investor relations section of the Johnson & Johnson website at investor.jnj.com.
Please note that this presentation contains forward-looking statements regarding among other things, the company’s future operating and financial performance, market position, and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording and are subject to certain risk and uncertainties that may cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties, and other factors can be found in our SEC filings, including our 2023 Form 10-K, which is available at investor.jnj.com and on the SEC's website.
Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships.
Moving to today's agenda, I will start by reviewing the second quarter sales and P&L results for the corporation, as well as highlights related to our two businesses. Joe Wolk, our CFO, will then provide additional business and financial commentary before sharing an overview of our cash position, capital allocation priorities, and guidance for 2024. Joaquin Duato, our Chairman and CEO, will then provide some closing remarks before we open it up for questions. Jennifer Taubert, John Reed, and Tim Schmid, our innovative medicine and MedTech leaders will be joining us for Q&A.